PULMONARY ARTERIAL HYPERTENSION IN β-THALASSEMIA MAJOR PATIENTS: SYMPTOM & QUALITY OF LIFE IMROVEMENT AFTER TREATMENT WITH BOSENTAN

被引：0
|
作者：
Farmaki, K. [1 ]
Kolymbianaki, P. [1 ]
Tzoumari, I. [1 ]
Pappa, C. [1 ]
Kariofillis, P. [2 ]
Voudris, V. [2 ]
机构：
[1] Gen Hosp Corinth, Corinth, Greece
[2] Onassis Cardiac Surg Ctr, Dept Cardiol 22, Athens, Greece
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2002
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [41] PALOSURAN TREATMENT, EFFECTIVE AS BOSENTAN IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) MODEL
    Onat, A. Mesut
    Pehlivan, Y.
    Demir, T.
    Kaplan, D. Sinan
    Orkmez, M.
    Turkebeyler, I. Halil
    Taysi, S.
    Kisacik, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 328 - 329
  • [42] Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan treatment due to lack of efficacy
    Benza, R. L.
    Mehta, S.
    Koegh, A.
    Lawrence, E. C.
    Oudiz, R. J.
    Barst, R. J.
    EUROPEAN HEART JOURNAL, 2005, 26 : 79 - 79
  • [43] Factors related to the quality of life in patients with pulmonary arterial hypertension
    Sarzynska, K.
    Polanski, J.
    Kopec, G.
    Mroczek, E.
    Jankowska-Polanska, B.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2021, 20 : 111 - 111
  • [44] Emotional symptoms and quality of life in patients with pulmonary arterial hypertension
    Vanhoof, Jasper M. M.
    Delcroix, Marion
    Vandevelde, Ellen
    Denhaerynck, Kris
    Wuyts, Wim
    Belge, Catharina
    Dobbels, Fabienne
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (08): : 800 - 808
  • [45] Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease
    Kotlyar, Eugene
    Sy, Raymond
    Keogh, Anne M.
    Kermeen, Fiona
    Macdonald, Peter S.
    Hayward, Christopher S.
    McNeil, Keith D.
    Celermajer, David S.
    CARDIOLOGY IN THE YOUNG, 2006, 16 (03) : 268 - 274
  • [46] Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
    Provencher, S
    Sitbon, O
    Simonneau, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (08) : 1337 - 1348
  • [47] Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension
    Matura, Lea Ann
    McDonough, Annette
    Carroll, Diane L.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (01) : 25 - 32
  • [48] Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing Bosentan treatment due to lack of efficacy
    Benza, RL
    Mehta, S
    Koegh, A
    Lawrence, EC
    Oudiz, RJ
    Barst, RJ
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 304 - +
  • [49] Long-term bosentan treatment in children with pulmonary arterial hypertension
    Standing, JF
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (09) : 1914 - 1915
  • [50] Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
    Sitbon, O.
    Beghetti, M.
    Petit, J.
    Iserin, L.
    Humbert, M.
    Gressin, V.
    Simonneau, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 : 25 - 31
12345